We now know there is not just one breast cancer. Because treatment that targets a woman’s specific breast cancer is more likely to be successful, identifying the specific cancer subtype is crucial to creating the right treatment plan. This type of personalized healthcare has been made possible by Roche’s advanced immunohistochemistry (IHC) and in situ hybridization (ISH) diagnostic solutions.
